bullish

GRCE: FY:25 Second Quarter Results

127 Views18 Nov 2024 23:00
Issuer-paid
Grace is a clinical-stage, biotechnology company focused on rare disease. Its lead program, GTX-104, is a novel injectable formulation of...
What is covered in the Full Insight:
  • Introduction
  • Financial Highlights
  • Pipeline and Clinical Progress
  • Future Milestones and Catalysts
  • Conclusion
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 11-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Zacks Small Cap Research
Research Coverage on Small and Micro-Cap Companies
Zacks Small Cap Research
Equity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x